Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.560
+0.020 (0.79%)
At close: Apr 28, 2026, 4:00 PM EDT
2.550
-0.010 (-0.39%)
After-hours: Apr 28, 2026, 5:58 PM EDT
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,980,235
Market Cap
13.66M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - | 17 | 0 |
| Dec 31, 2024 | 17 | -1 | -5.56% | 17 | 0 |
| Dec 31, 2023 | 18 | -1 | -5.26% | 18 | 0 |
| Dec 31, 2022 | 19 | 2 | 11.76% | 15 | 4 |
| Dec 31, 2021 | 17 | 2 | 13.33% | 13 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Lunai Bioworks | 29 |
| Citius Pharmaceuticals | 23 |
| BioCardia | 21 |
| SeaStar Medical Holding | 17 |
| Intensity Therapeutics | 7 |
| Phio Pharmaceuticals | 6 |
| Jupiter Neurosciences | 5 |
| Kairos Pharma | 4 |
MBRX News
- 5 days ago - Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026 - GlobeNewsWire
- 7 days ago - Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 21 days ago - Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile - GlobeNewsWire
- 5 weeks ago - Moleculin Biotech Transcript: The 38th Annual Roth Conference - Transcripts
- 5 weeks ago - Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout - GlobeNewsWire
- 5 weeks ago - Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 - GlobeNewsWire
- 6 weeks ago - Moleculin to Present at 38th Annual ROTH Conference - GlobeNewsWire
- 6 weeks ago - Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study - GlobeNewsWire